Liver disease associated mortality in HIV: 1995–2003 GERMIVIC
ESLD assoc. death:
% total mortality
ESLD assoc. death:
% HBsAg+
Rosenthal E et al  J Viral Hepat 2007;14:183−8
ESLD = End-stage liver disease
These data are consistent with a recent observation in the French GERMIVIC cohort. In this cohort in 2003 proportion of liver related death shows a slight decrease and there is a stabilization from 2001 to 2003 after some years of progressive increase. In the same period the proportion of liver related death occurring in HBsAg positive subjects  showed a sharp decrease. These data indirectly support the hypothesis that HBV related mortality is decreasing with the availability of anti-retrovirals with anti HBV activity and that this decrease is one of the causes in the stabilization of liver related mortality observed in HIV infected patients in some very recent reports.